Affiliation:
1. McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Canada
2. Research Facilitation, Alberta Health Services, Calgary, Canada
Abstract
Abstract
Context
More than 3% of adults report vitamin D intakes of 4000 IU/day or more, but the safety of this practice is unknown.
Objective
The objective of this work is to establish whether vitamin D doses up to 10 000 IU/day are safe and well tolerated.
Design
The Calgary Vitamin D Study was a 3-year, double-blind, randomized controlled trial.
Setting
A single-center study was conducted at the University of Calgary, Canada.
Participants
Participants included healthy adults (n = 373) ages 55 to 70 years with serum 25-hydroxyvitamin D 30 to 125 nmol/L.
Interventions
Participants were randomly assigned 1:1:1 to vitamin D3 400, 4000, or 10 000 IU/day. Calcium supplementation was initiated if dietary calcium intake was less than 1200 mg/day.
Main Outcome Measures
In these prespecified secondary analyses, changes in serum 25-hydroxyvitamin D, calcium, creatinine, 24-hour urine calcium excretion, and incidence of adverse events were assessed. Between-group differences in adverse events were examined using incident rate differences and logistic regression.
Results
Of 373 participants (400: 124, 4000: 125, 10 000: 124), 49% were male, mean (SD) age was 64 (4) years, and 25-hydroxyvitamin D 78.0 (19.5) nmol/L. Serum calcium, creatinine, and 24-hour urine calcium excretion did not differ between treatments. Mild hypercalcemia (2.56-2.64 mmol/L) occurred in 15 (4%) participants (400: 0%, 4000: 3%, 10 000: 9%, P = .002); all cases resolved on repeat testing. Hypercalciuria occurred in 87 (23%) participants (400: 17%, 4000: 22%, 10 000: 31%, P = .01). Clinical adverse events were experienced by 365 (97.9%) participants and were balanced across treatment arms.
Conclusions
The safety profile of vitamin D supplementation is similar for doses of 400, 4000, and 10 000 IU/day. Hypercalciuria was common and occurred more frequently with higher doses. Hypercalcemia occurred more frequently with higher doses but was rare, mild, and transient.
Funder
Pure North S’Energy Foundation
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism